REG - Sareum Holdings PLC - Results of EGM

Sareum HoldingsAnnouncement

28/02/2022 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220228:nRSb0774Da&default-theme=true

RNS Number : 0774D  Sareum Holdings PLC  28 February 2022

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of EGM

Cambridge, UK, 28 February 2022 - Sareum Holdings plc (AIM: SAR), the
specialist drug development company delivering targeted small molecule
therapeutics to improve the treatment of cancer and autoimmune diseases, held
its Extraordinary General Meeting ("EGM") today and all resolutions were duly
passed. Details of the proxy voting are shown in the table below.

 Special resolution                                                             Votes For    %     Votes Against  %     Votes Total (excluding withheld)  % of ISC Voted  Votes Withheld

 1. New articles of association produced to the meeting be adopted as articles  813,549,009  86.3  129,225,243    13.7  942,774,252                       27.7            4,669,024
 of association of the Company

 

 Ordinary resolution                                                           Votes For    %     Votes Against  %     Votes Total (excluding withheld)  % of ISC Voted  Votes Withheld

 2. Every 50 ordinary shares of 0.00025 GBP each in capital of the Company be  809,024,537  85.6  135,837,347    14.4  944,861,884                       27.8            2,581,392
 consolidated into one new ordinary share of 0.0125 GBP

ISC - Issued Share Capital

Share Consolidation

Following the approval of Resolution 2, every 50 ordinary shares of 0.00025
pence each (the "Existing Shares") that are in issue as at 6.00 p.m. today
will be consolidated into one new ordinary share of 0.0125 pence each (the
"New Ordinary Shares"). Other than the change in nominal value, the New
Ordinary Shares arising on implementation of the share consolidation will have
the same rights as the Existing Ordinary Shares, including voting and other
rights.

It is expected that the New Ordinary Shares arising from the share
consolidation will be admitted to trading AIM from 8.00 a.m. on 1 March 2022
("Admission") with ISIN number GB00BMC3RJ87.

Immediately following Admission, the Company will have 68,069,416 ordinary
shares of 0.0125 pence each in issue; therefore the total voting rights in the
Company will be 68,069,416. This figure may be used by shareholders in the
Company as the denominator for the calculations by which they may determine if
they are required to notify their interest in, or a change to their interest
in, the share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

The full text of each of the resolutions is set out in the Notice of EGM,
available in the Investors section of the Company's website
(www.sareum.com/investors (http://www.sareum.com/investors/document-centre/)
).

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                    01223 497700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                          020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel                                          020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                         020 3764 2341

 MEDiSTRAVA Consulting (Financial PR)

 Mark Swallow / George Underwood / Evelyn McCormack   020 3928 6900

 

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.

SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMSEIFIAEESELE